Natera completed the acquisition of Foresight Diagnostics for $450m.

Natera, a company specializing in cell-free DNA and precision medicine, completed the acquisition of Foresight Diagnostics, a company specializing in ultrasensitive molecular residual disease (MRD) detection, for $450m. “This acquisition reinforces Natera’s position at the forefront of precision oncology. Foresight’s phased variant technology and leadership in lymphoma complement Natera’s strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners and the broader healthcare system," Steve Chapman, Natera CEO.